CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...

Dexfenfluramine, aka Redux (also called “fen-phen” in combination with phentermine), was sold in the 1990s until it was ...

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

The seventh edition of the International Meeting on Pulmonary Hypertension Clinical Treatment (IMPAHCT), organized by the ...

A small, multi-country analysis of women of child-rearing age has found that these patients experience limits on activities ...

Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and pulmonary hypertension were found.

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that I had mild to moderate mitral stenosis with ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...

Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.